我要投票 HYK华因康在基因检测行业中的票数:248
· 外 推 电 报 ·
2025-05-10 17:33:28 星期六

【HYK华因康是哪个国家的品牌?】

HYK华因康是什么牌子?「HYK华因康」是 深圳华因康基因科技有限公司 旗下著名品牌。该品牌发源于广东,由创始人盛司在2008-01-23期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力HYK华因康品牌出海!将品牌入驻外推网,定制HYK华因康品牌推广信息,可以显著提高HYK华因康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

华因康集团秉承“专业、严谨、创新、服务”的理念,自2008年创立以来,一直致力于中华民族健康事业,发展迅猛。迄今拥有深圳市华因康高通量生物技术研究院、深圳华因康基因科技有限公司、华因康基因检测中心及全国各地多家分支机构,成为以基因技术为核心,拥有雄厚研发支撑、具备研发、生产和应用三位一体的完整产业链的生物技术高科技集团。

研发中心–深圳市华因康高通量生物技术研究院拥有一支在机械、光学、电子、生化、软件、生物信息、生物医疗等技术领域具备尖端技术成果的科学家、教授、博士、博士后及行业专家组成的精英技术团队。研究院面向世界科学前沿和国家战略发展需求,以新型DNA测序分析技术的突破为契机,旨在研究高通量生物技术,开发高通量实验和检测设备,寻找高通量检测新方法,为我国生命科技领域的上游进行产业布局,搭建与基因技术相关的生命科技产业基础性研究平台,进行国际前沿基因组科学基础及应用研究与技术开发,提升我国基因技术自主创新能力。

产品中心-深圳华因康基因科技有限公司专业生产、销售高通量基因测序设备、生物试剂和基因信息分析软件,提供科研技术服务与生物信息数据分析技术服务。公司主导产品PSTAR高通量基因测序系统,填补了我国在生命科技产业核心装备、基因测序设备制造、试剂生产与生物信息分析服务等领域的空白,广泛应用于生命科学基础研究、临床诊断与治疗、疾病预防与保健以及新药研制等领域。

基因检测中心-华因康基因检测中心依托于华因康基因新一代高通量基因测序系统平台技术,是转化医学的专业化服务机构。中心以新一代高通量基因测序系统技术平台为核心,辅以实时荧光PCR平台、STR分析平台、免疫组化、荧光原位杂交等技术平台,覆盖了DNA、RNA、蛋白水平,测序、PCR、蛋白免疫组化、FISH等多种检测技术。已率先研发出多种适用于亚洲人的临床基因检测项目,专业提供“肿瘤个体化用药指导靶基因检测”临床技术服务,同时为临床提供疾病早期筛查、重大疾病分子标志物检测及与保健、优生优育相关的检测服务。与国内顶级医院及科研机构携手,开拓高通量基因测序技术在生命科学与医疗健康领域中的广阔应用,为人类的健康事业提供专业、贴心的个性化服务。

华因康基因(集团)将始终坚持“探索基因信息,提高生命价值”的宗旨,致力于打造基因生命科技在研发、应用、临床转化系统平台技术上的核心竞争力,彰显中国基因产业在世界竞争中的领航者地位,引领中国健康产业发展新方向。


英文翻译:Huayinkang group adheres to the concept of "professional, rigorous, innovative and service". Since its establishment in 2008, it has been committed to the cause of health of the Chinese nation, with rapid development. So far, it has Shenzhen huayinkang high throughput Biotechnology Research Institute, Shenzhen huayinkang Gene Technology Co., Ltd., huayinkang gene testing center and many branches all over the country. It has become a biotechnology high-tech group with gene technology as the core, strong R & D support, and a complete industrial chain of R & D, production and application. R & D Center - Shenzhen huayinkang high throughput Biotechnology Research Institute has an elite technical team composed of scientists, professors, doctors, postdoctors and industry experts with cutting-edge technical achievements in the fields of machinery, optics, electronics, biochemistry, software, biological information, biomedicine and other technical fields. Facing the needs of the world's scientific frontier and national strategic development, and taking the breakthrough of new DNA sequencing analysis technology as an opportunity, the research institute aims to study high-throughput biotechnology, develop high-throughput experiment and detection equipment, find new high-throughput detection methods, make industrial layout for the upstream of China's life science and technology field, and build a basic research platform of life science and technology industry related to gene technology To carry out basic and applied research and technological development of international frontier genomic science and improve the independent innovation ability of China's gene technology. Product Center - Shenzhen huayinkang Gene Technology Co., Ltd. specializes in the production and sales of high-throughput gene sequencing equipment, biological reagents and gene information analysis software, providing scientific research and technical services and biological information data analysis technical services. The company's leading product, pstar high-throughput gene sequencing system, has filled in the gaps in the core equipment of life science and technology industry, gene sequencing equipment manufacturing, reagent production and bio information analysis services in China, and is widely used in basic research of life science, clinical diagnosis and treatment, disease prevention and health care, and new drug development and other fields. Based on the platform technology of new generation high-throughput gene sequencing system of huayinkang gene, huayinkang gene testing center is a professional transformation medicine service organization. The center takes the new generation high-throughput gene sequencing system technology platform as the core, supplemented by real-time fluorescent PCR platform, STR analysis platform, immunohistochemistry, fluorescence in situ hybridization and other technology platforms, covering DNA, RNA, protein level, sequencing, PCR, protein immunohistochemistry, fish and other detection technologies. It has taken the lead in developing a variety of clinical gene detection projects suitable for Asians, providing professional clinical technical services of "tumor individualized drug use guidance target gene detection", and providing early disease screening, detection of major disease molecular markers and detection services related to health care, eugenics and eugenics. Together with the top domestic hospitals and scientific research institutions, we will explore the wide application of high-throughput gene sequencing technology in the field of life science and medical health, and provide professional and intimate personalized services for human health. Huayinkang gene (Group) will always adhere to the tenet of "exploring gene information and improving life value", devote itself to building the core competitiveness of gene life technology in research and development, application and clinical transformation system platform technology, highlight the leading position of China's gene industry in the world competition, and lead the new development direction of China's health industry.

本文链接: https://www.waitui.com/brand/4c1ad289a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

奥乐齐昆山首店正式开业

36氪获悉,5月10日,奥乐齐ALDI位于昆山的首家门店正式开业。这是奥乐齐在苏州、无锡成功开设两家门店且大受本地居民欢迎与认可之后,于江苏地区布局的又一重要里程碑。短时间内在苏锡昆“连开三店”,不仅凸显出奥乐齐广受当地受众认可,亦彰显了其对本地消费市场的坚定信心,更标志着品牌在江苏市场战略布局的进一步拓展与深化。

2小时前

浙江大学董雪兵:强化产业创新协同 发挥区域战略叠加效应

5月9日,2025长三角粤港澳国家战略联动发展论坛在广州举行。论坛前夕,上海证券报记者就如何深化区域联动等问题,采访浙江大学区域协调发展研究中心副主任董雪兵。董雪兵认为,长三角、粤港澳大湾区等重点区域应在服务国家战略需求的基础上,发挥战略叠加效应,实现进一步联动发展。以产业协同为例,长三角和粤港澳大湾区可以发挥各自优势,围绕生物医药、人工智能、集成电路等双方均具优势的领域,开展创新链、产业链、供应链和价值链的空间融合,共同打造全国领先的产业集群。(上证报)

2小时前

永达股份:子公司部分产品应用于机器人领域,业务规模尚小

永达股份(001239)5月9日在业绩说明会上表示,公司控股子公司江苏金源高端装备有限公司部分产品应用于机器人领域,但在此领域的业务规模尚小。(e公司)

2小时前

《中国企业海外传播力分析报告(2024)》正式发布

《中国企业海外传播力分析报告(2024)》在于浙江德清举办的2025世界品牌莫干山大会上正式发布。《报告》发现,中国企业的国际传播及形象打造策略获得实效。中国企业早期的形象宣传多集中于技术革新的宏大叙事或文化符号的堆叠,而当前实践更强调多维度资源的整合。中国企业的海外形象建构策略正在经历从“单一功能输出”向“多维价值融合”的转型,其核心在于通过技术、文化与社会责任的动态协同,构建更具韧性的品牌叙事。例如,作为中国全球化企业代表之一,海信将“环境、社会、治理”(ESG)理念深度融入全球化发展,构建了独具特色的国际传播模式。(财联社)

2小时前

烨隆股份撤回上市申请

上海证券报记者从上交所获悉,过会已一年多的无锡烨隆精密机械股份有限公司5月8日撤回上市申请,上交所主板IPO终止。(上证报)

2小时前

本页详细列出关于HYK华因康的品牌信息,含品牌所属公司介绍,HYK华因康所处行业的品牌地位及优势。
咨询